Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 31;13(12):6603-6607.
doi: 10.21037/tcr-24-1716. Epub 2024 Dec 26.

Locally advanced non-small cell lung cancer: search for the optimal radiotherapy continues

Naoko Katsurada  1 , Motoko Tachihara  1
Affiliations
Editorial

Locally advanced non-small cell lung cancer: search for the optimal radiotherapy continues

Naoko Katsurada et al. Transl Cancer Res. .
No abstract available

Keywords: Adaptive radiotherapy; hypofractionation; non-small cell lung cancer (NSCLC); stereotactic body radiation therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-24-1716/coif). M.T. reports that she has received grants from AstraZeneca K.K. and received honoraria as a speaker from AstraZeneca K.K.. The other author has no conflicts of interest to declare.

Comment on

Similar articles

See all similar articles

References

    1. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2022;40:1301-11. 10.1200/JCO.21.01308 - DOI - PMC - PubMed
    1. Jang JY, Song SY, Shin YS, et al. Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Insights from Real-World Data. Cancer Res Treat 2024;56:785-94. 10.4143/crt.2023.1014 - DOI - PMC - PubMed
    1. Machtay M, Paulus R, Moughan J, et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol 2012;7:716-22. 10.1097/JTO.0b013e3182429682 - DOI - PMC - PubMed
    1. Wu TC, Luterstein E, Neilsen BK, et al. Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncol 2024;10:352-9. 10.1001/jamaoncol.2023.6033 - DOI - PMC - PubMed
    1. Bradley JD, Hu C, Komaki RR, et al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2020;38:706-14. 10.1200/JCO.19.01162 - DOI - PMC - PubMed

LinkOut - more resources